National Utilization and Expenditure Trends of GLP-1 Receptor Agonists and Dual GLP-1/GIP Agonist in Croatia, 2017–2024

<i>Background and Objectives</i>: GLP-1 receptor agonists (GLP-1 RAs; ATC A10BJ) and dual GLP-1/GIP agonist (ATC A10BX16) have expanded rapidly due to strong evidence in type 2 diabetes, obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). Their high acquisition costs and ac...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Mate Car, Damir Erceg, Mario Udovičić, Tomislav Bokun, Dario Rahelić
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2025-12-01
Edice:	Medicina
Témata:	antihyperglycemic drugs pharmacoepidemiology GLP-1 receptor agonists dual GLP-1/GIP agonist SGLT-2 inhibitors Croatia
On-line přístup:	https://www.mdpi.com/1648-9144/61/12/2210
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!